# BIOVENTUS INC. (BVS) FY2026 YTD Q2 P&L / Income Statement

- Company: BIOVENTUS INC. (BVS)
- Period: 2026-01-01 to 2026-06-27
- Filing: Q2 FY2026 10-Q, filed 2026-08-05, accession number 0001665988-26-000042
- Page: https://plicit.ai/financials/bvs/fy2026-ytd-q2-income-statement
- Chart image: https://plicit.ai/charts/bvs-fy2026-ytd-q2-income-statement-sankey.png

## Chart details: Revenue by Product and Service by Geography

Income statement for 2026-01-01 through 2026-06-27. View: Product and Service by Geographical. Revenue uses this breakdown; costs and expenses retain the consolidated categories.

- **Net sales**: 285,297,000 US dollars
- **Cost of sales (including depreciation and amortization of $9,893, $10,603, $19,980 and $20,868, respectively)**: 88,862,000 US dollars
- **Gross profit**: 196,435,000 US dollars
- **Operating costs, net of other operating income (calculated)**: 168,892,000 US dollars
- **Operating income**: 27,543,000 US dollars
- **Other expense**: negative 7,718,000 US dollars
- **Income before income taxes**: 19,825,000 US dollars
- **Income tax (benefit) expense, net**: negative 20,326,000 US dollars
- **Net income**: 40,151,000 US dollars
- **Pain Treatments - UNITED STATES**: 128,861,000 US dollars
- **Pain Treatments - International**: 16,313,000 US dollars
- **Restorative Therapies - UNITED STATES**: 35,923,000 US dollars
- **Restorative Therapies - International**: 5,820,000 US dollars
- **Surgical Solutions - UNITED STATES**: 86,126,000 US dollars
- **Surgical Solutions - International**: 12,254,000 US dollars
- **Selling, general and administrative expense**: 161,065,000 US dollars
- **Research and development expense**: 5,640,000 US dollars
- **Restructuring costs**: 39,000 US dollars
- **Depreciation and amortization**: 2,148,000 US dollars
- **Loss on disposals**: 0 US dollars

### Chart connections

- Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
- Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.
- Of which attributable to BIOVENTUS INC.: $36.55 M; to noncontrolling interests: $3.60 M.

## Chart details: Revenue by Business Segment

- Page: https://plicit.ai/financials/bvs/fy2026-ytd-q2-income-statement/revenue-by-business-segment
- Chart image: https://plicit.ai/charts/bvs-fy2026-ytd-q2-revenue-by-business-segment-sankey.png

Income statement for 2026-01-01 through 2026-06-27. View: Business segment. Revenue uses this breakdown; costs and expenses retain the consolidated categories.

- **Net sales**: 285,297,000 US dollars
- **Cost of sales (including depreciation and amortization of $9,893, $10,603, $19,980 and $20,868, respectively)**: 88,862,000 US dollars
- **Gross profit**: 196,435,000 US dollars
- **Operating costs, net of other operating income (calculated)**: 168,892,000 US dollars
- **Operating income**: 27,543,000 US dollars
- **Other expense**: negative 7,718,000 US dollars
- **Income before income taxes**: 19,825,000 US dollars
- **Income tax (benefit) expense, net**: negative 20,326,000 US dollars
- **Net income**: 40,151,000 US dollars
- **US Segment**: 250,910,000 US dollars
- **International Segment**: 34,387,000 US dollars
- **Selling, general and administrative expense**: 161,065,000 US dollars
- **Research and development expense**: 5,640,000 US dollars
- **Restructuring costs**: 39,000 US dollars
- **Depreciation and amortization**: 2,148,000 US dollars
- **Loss on disposals**: 0 US dollars

### Chart connections

- Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
- Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.
- Of which attributable to BIOVENTUS INC.: $36.55 M; to noncontrolling interests: $3.60 M.

## Chart details: Revenue by Geography

- Page: https://plicit.ai/financials/bvs/fy2026-ytd-q2-income-statement/revenue-by-geography
- Chart image: https://plicit.ai/charts/bvs-fy2026-ytd-q2-revenue-by-geography-sankey.png

Income statement for 2026-01-01 through 2026-06-27. View: Geography. Revenue uses this breakdown; costs and expenses retain the consolidated categories.

- **Net sales**: 285,297,000 US dollars
- **Cost of sales (including depreciation and amortization of $9,893, $10,603, $19,980 and $20,868, respectively)**: 88,862,000 US dollars
- **Gross profit**: 196,435,000 US dollars
- **Operating costs, net of other operating income (calculated)**: 168,892,000 US dollars
- **Operating income**: 27,543,000 US dollars
- **Other expense**: negative 7,718,000 US dollars
- **Income before income taxes**: 19,825,000 US dollars
- **Income tax (benefit) expense, net**: negative 20,326,000 US dollars
- **Net income**: 40,151,000 US dollars
- **UNITED STATES**: 250,910,000 US dollars
- **International**: 34,387,000 US dollars
- **Selling, general and administrative expense**: 161,065,000 US dollars
- **Research and development expense**: 5,640,000 US dollars
- **Restructuring costs**: 39,000 US dollars
- **Depreciation and amortization**: 2,148,000 US dollars
- **Loss on disposals**: 0 US dollars

### Chart connections

- Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
- Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.
- Of which attributable to BIOVENTUS INC.: $36.55 M; to noncontrolling interests: $3.60 M.